

l Fw



Docket No.: 68970-235077
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Francisco Javier Vila Pahi et al.

Art Unit: Not Yet Assigned

Application No: 10/590,311

Examiner: Not Yet Assigned

Confirmation No: Not Yet Assigned

Filed: August 23, 2006

Atty. Docket No: 68970-235077

For: NEW THERAPEUTIC USE FOR A
GROUP OF SULPHATED
POLYSACCHARIDES

Customer No:

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO/SB/08A and which the Examiner may deem relevant to patentability of the claims of the above-identified application. Copies of the documents are submitted herewith.

It is believed that no fee is due for the submission of this Information Disclosure Statement. However, if any additional fee is required, please charge any necessary fee or credit any

overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Dated:


Feb 12 2007

Respectfully submitted,

By *[Signature]*
Marina V. Schneller

Registration No.: 26,032
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

DC2DOCS1/827819



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2006

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT	(\$)	0.00	Attorney Docket No. 68970-235077
--------------------------------	------	------	----------------------------------

Complete if Known

Application Number	10/590,311
Filing Date	August 23, 2006
First Named Inventor	Francisco J. Vila Pahi
Examiner Name	Not Yet Assigned
Art Unit	Not Yet Assigned

METHOD OF PAYMENT (check all that apply)

<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	<input type="checkbox"/> Money Order	<input type="checkbox"/> None	<input type="checkbox"/> Other (please identify): _____
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 22-0261	Deposit Account Name: _____		Venable LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

<input type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		<u>Fees Paid (\$)</u>
	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEESFee Description

Each claim over 20 (including Reissues)

<u>Fee (\$)</u>	<u>Small Entity</u>
50	25
200	100
360	180

Each independent claim over 3 (including Reissues)

Multiple dependent claims

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>
25	- 25 =	x	=	<u>Fee (\$)</u> <u>Fee Paid (\$)</u>

HP = highest number of total claims paid for, if greater than 20.

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
4	- 4 =	x	=

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
_____	- 100 =	/50 (round up to a whole number) x	_____	=

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge)

<u>SUBMITTED BY</u>		<u>Registration No. (Attorney/Agent)</u>	<u>Telephone</u>
Signature		26,032	(202) 344-4000
Name (Print/Type)	Marina V. Schneller	Date	

DC2DOCS1/827822



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	10/590,311
				Filing Date	August 23, 2006
				First Named Inventor	Francisco Javier Vila PAHI et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number 68970-235077	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (<i>if known</i>)	MM-DD-YYYY		
	AA				
	AB				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		
	BA				
	BB				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	JORDAN, K.M. et al., "EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT); <i>Ann Rheum Dis.</i> 2003; 62, 1145-1155.			
	CB	ALTMAN, R. et al., "Development of Criteria for the Classification and Reporting of Osteoarthritis", <i>Arthritis and Rheumatism</i> , Vol. 29, No. 8, August 1986, pp. 1039-1049.			
	CC	KLIPPEL, John H. et al., "Osteoarthritis and Related Disorders", <i>PHEUMATOLOGY</i> , 2 ND Ed.,			
	CD	LEQUESNE, M., "Symptomatic Slow-Acting Drugs in Osteoarthritis: A Novel Therapeutic Concept?", <i>Expansion Scientifique Francaise</i> , 1994, 69-73.			
	CE	HARRIS, Edward D., RHEUMATOID ARTHRITIS, "Pathophysiology and Implications of Therapy", <i>The New England Journal of Medicine</i> , Vol. 322, No. 18, May 3, 1990, pps. 1277-1289.			
	CF	HOCHBERG, Marc C., "Adult and Juvenile Rheumatoid Arthritis: Current Epidemiologic Concepts", <i>EPIDEMIOLOGIC REVIEWS - THE JOHNS HOPKINS UNIVERSITY SCHOOL OF HYGIENE AND PUBLIC HEALTH</i> , Vol. 3, 1981, pp. 27-44.			
	CG	Committee for Proprietary Medicinal Products (CPMP), "Points to Consider on Clinical Investigation of Medicinal Products Other than NSAIDS for Treatment of Rheumatoid Arthritis", <i>The European Agency for the Evaluation of Medicinal Products</i> , London, December 17, 2003.			
	CH	COMBE, Bernard et al., "Eular Recommendations for the Management of Early Arthritis: Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)", <i>Ann Rheum Dis.</i> , ARD Online First, published January 5, 2006, www.ard.bmjjournals.com , pps. 1-24.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered
--------------------	--	-----------------